XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Common Stock Reserved for Future Issuances
As of June 30, 2024, the Company had reserved Common Stock for future issuances as follows:
June 30,
2024
Common stock reserved for Contingent Earnout Shares15,000,000 
Common stock reserved for Option Agreement1,333,334 (1)
Exercise of options outstanding under stock plans12,521,655 
Options available for issuance under stock plans5,809,549 
Shares available for grant under ESPP1,030,033 
Warrants to purchase Common Stock5,588,506 
41,283,077 
___________________________
(1)Assumes the exercise of the entire Option as provided for in the Option Agreement at the minimum purchase price of $7.50 per share.
Schedule of Common Stock Warrants Outstanding
The Company had the following Common Stock warrants outstanding as of June 30, 2024 and December 31, 2023:
Common Stock Warrants Outstanding
Legacy Humacyte Common Stock Warrants411,006 
Private Placement Warrants177,500 
Public Warrants5,000,000 
Total Common Stock Warrants5,588,506 
Schedule of Assumptions Used in the Valuations
The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:
June 30,
2024
December 31,
2023
Market price of public stock$4.80$2.84
Exercise price$11.50$11.50
Expected term (years)2.162.65
Expected share price volatility96.0 %75.0 %
Risk-free interest rate4.68 %4.09 %
Estimated dividend yield%%
Assumptions used in the valuations are described below:
June 30,
2024
December 31,
2023
Current stock price$4.80$2.84
Expected share price volatility88.6 %86.7 %
Risk-free interest rate4.36 %3.88 %
Estimated dividend yield%%
Expected term (years)10.0010.00